Subconjunctival draining minimally-invasive glaucoma devices for medically uncontrolled glaucoma
- 16 December 2018
- journal article
- review article
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2018 (12) , CD012742
Abstract
Background Glaucoma is a leading cause of irreversible blindness. Subconjunctival draining minimally‐invasive glaucoma devices such as the Xen gelatin implant and InnFocus stent have been introduced as a treatment to prevent glaucoma progressing. These implants provide a channel to allow aqueous humour from the anterior chamber of the eye to drain into the subconjunctival space on the surface of the eye thus reducing intraocular pressure (IOP) and mimicking the mechanism of the most commonly undertaken glaucoma surgery, trabeculectomy. Objectives To evaluate the efficacy and safety of subconjunctival draining minimally‐invasive glaucoma devices in treating people with open angle glaucoma and ocular hypertension whose condition is inadequately controlled with drops. Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL; which contains the Cochrane Eyes and Vision Trials Register; 2018, Issue 6); Ovid MEDLINE; Ovid Embase; the ISRCTN registry; ClinicalTrials.gov and the WHO ICTRP. The date of the search was 10 July 2018. Selection criteria We searched for randomised controlled trials (RCTs) of Xen gelatin implant or InnFocus MicroShunt to other surgical treatments (other minimally‐invasive glaucoma device techniques, trabeculectomy), laser treatment or medical treatment. We also planned to include trials where these devices were combined with phacoemulsification compared to phacoemulsification alone. Data collection and analysis We planned to have two review authors independently extract data from reports of included studies using a data collection form and analyse data based on methods expected by Cochrane. Our primary outcome was mean change in IOP. Secondary outcomes included proportion of participants who were drop‐free; proportion of participants who achieved an IOP of 21 mmHg or less, 17 mmHg or less or 14 mmHg or less; and proportion of participants experiencing intra‐ and postoperative complications. We planned to measure all outcomes in the short‐term (six to 18 months), medium‐term (18 to 36 months), and long‐term (36 months onwards). Main results We found no completed RCTs that met our inclusion criteria. We found one ongoing study (NCT01881425). The study compares InnFocus MicroShunt to trabeculectomy in people with primary open angle glaucoma. The primary outcome is greater than 20% IOP reduction from baseline to 12 months' follow‐up. A total of 889 people aged between 40 and 85 years have been enrolled. The estimated study completion date is November 2019. Authors' conclusions There is currently no high‐quality evidence for the effects of subconjunctival draining minimally‐invasive glaucoma devices for medically uncontrolled open angle glaucoma. Properly designed RCTs are needed to assess the medium‐ and long‐term efficacy and safety of this technique.Keywords
This publication has 36 references indexed in Scilit:
- Lifetime Risk of Blindness in Open-Angle GlaucomaAmerican Journal of Ophthalmology, 2013
- Reduction in Intraocular Pressure after Cataract Extraction: The Ocular Hypertension Treatment StudyOphthalmology, 2012
- Postoperative Complications in the Tube Versus Trabeculectomy (TVT) Study During Five Years of Follow-upAmerican Journal of Ophthalmology, 2012
- Risk Factors for Poor Adherence to Eyedrops in Electronically Monitored Patients with GlaucomaOphthalmology, 2009
- Adherence with Topical Glaucoma Medication Monitored ElectronicallyOphthalmology, 2009
- Medical applications of poly(styrene-block-isobutylene-block-styrene) (“SIBS”)Biomaterials, 2008
- The number of people with glaucoma worldwide in 2010 and 2020British Journal of Ophthalmology, 2006
- Interim clinical outcomes in the collaborative initial glaucoma treatment study comparing initial treatment randomized to medications or surgeryOphthalmology, 2001
- The advanced glaucoma intervention study (AGIS): 7. the relationship between control of intraocular pressure and visual field deteriorationAmerican Journal of Ophthalmology, 2000
- Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressuresAmerican Journal of Ophthalmology, 1998